News
1d
Interesting Engineering on MSNChinese firm nears solar efficiency record with 34.58% perovskite-silicon cellChinese solar module maker Longi has presented a new tandem perovskite-silicon solar cell with a 34.58% power conversion ...
Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...
In a new scientific paper published in nature, the Chinese manufacturer presented a new tandem perovskite-silicon solar cell based on a bottom cell with a heterojunction design. It also used a new ...
In a new scientific paper published in nature, the Chinese manufacturer presented a new tandem perovskite-silicon solar cell based on a bottom cell with a heterojunction design. It also used a new ...
Organic-inorganic hybrid perovskite has been verified as a suitable semiconductor for hot carrier solar cells via transient absorption spectroscopy. Recently, an internally photoemitted hot carrier ...
Perovskite solar cells (PSCs) have shown a remarkable rise in power conversion efficiency in a few years' time. Despite this there are still hurdles in the way of commercialization., and their ...
Scientists in Japan have developed a device that enables external magnetic field control of magnetic injection current in the bulk photovoltaic effect (BPVE), a phenomenon not yet used in commercial ...
By Chioma Obinna On this year’s World Sickle Cell Day, healthcare professionals have called for multidisciplinary care, friendly policies, and massive awareness to reduce the challenges faced by ...
17don MSN
One of the most efficient forms of renewable energy, solar power, is generated by solar cells, which are the building blocks of solar panels. These electronic devices use semiconductors to convert the ...
It fabricates a monolayer of cells and has been described to maintain extracellular structures with minimal damage to the cell morphology and function for tissue reconstruction. (8,9) In clinical ...
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results